Nanobiotix S.A.

NasdaqGS:NBTX Stock Report

Market Cap: US$2.1b

Nanobiotix Past Earnings Performance

Past criteria checks 0/6

Nanobiotix's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 33.8% annually. Revenues have been growing at an average rate of 36.3% per year.

Key information

-1.11%

Earnings growth rate

9.55%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate36.30%
Return on equityn/a
Net Margin-73.52%
Last Earnings Update31 Dec 2025

Recent past performance updates

Recent updates

Seeking Alpha • Oct 23

Nanobiotix S.A: Behind The Recent Momentum

Summary Nanobiotix S.A. has recently surged on strong NBTXR3 data, but its sole asset is out-licensed to Johnson & Johnson. NBTXR3 shows promise in multiple cancer indications, especially head and neck, NSCLC, and melanoma, with pivotal readouts expected in 1H26. Despite potential blockbuster royalties, NBTX's $1.1B valuation appears stretched due to limited pipeline and reliance on J&J for development. An analysis around Nanobiotix follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.
Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.
Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.
Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

Revenue & Expenses Breakdown

How Nanobiotix makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:NBTX Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2533-242023
30 Sep 2521-382128
30 Jun 2510-522133
31 Mar 251-602137
31 Dec 24-7-682141
30 Sep 2418-512142
30 Jun 2442-332243
31 Mar 2439-372240
31 Dec 2336-402238
30 Sep 2321-492136
30 Jun 237-591934
31 Mar 236-581833
31 Dec 225-571833
30 Sep 224-501832
30 Jun 223-431931
31 Mar 223-451931
31 Dec 213-471930
30 Sep 212-451929
30 Jun 212-431827
31 Mar 212-391626
31 Dec 202-341524
30 Sep 202-411627
30 Jun 202-481730
31 Mar 202-491830
31 Dec 193-511930
30 Sep 193-461728
30 Jun 193-421525
31 Mar 193-361423
31 Dec 183-301321
30 Sep 184-281220
30 Jun 184-271119
31 Mar 184-261119
31 Dec 174-261118
30 Sep 174-251216
30 Jun 174-241216
31 Mar 175-231116
31 Dec 165-221017
30 Sep 165-211016
30 Jun 165-19916
31 Mar 165-18815
31 Dec 154-17714
30 Sep 154-15712
30 Jun 153-13611

Quality Earnings: NBTX is currently unprofitable.

Growing Profit Margin: NBTX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NBTX is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare NBTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NBTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43%).

Return on Equity

High ROE: NBTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/22 07:08
End of Day Share Price 2026/05/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanobiotix S.A. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Philippa GardnerEdison Investment Research
Jonathan MillerEvercore ISI
Emmanuel ParotGilbert Dupont